Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Lilly dives into vaccine research with 3 biotech buyouts including Vaccine Company at up to $1.55 billion for an Epstein-Barr virus program. The acquisitions…
LLY Acquires Vaccine Company Focused on Innovative Nanoparticle Technology. Vaccine Company is advancing a preclinical pipeline focused on various viral…
Eli Lilly to buy three small vaccine developers. The deal for Vaccine Company at up to $1.55 billion targets Epstein-Barr virus, which is linked to multiple…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Eli Lilly agreed to acquire Vaccine Company, Inc. for up to $1.55B (upfront plus milestones). Vaccine Company develops proprietary In Vivo Nanoparticle (IVN) technology that mimics virus-like-particle immunogenicity without traditional VLP manufacturing burden; lead Phase-1-ready candidate is a five-antigen Epstein-Barr Virus vaccine, with broader pipeline across viral pathogens. Part of Lilly's three-deal infectious disease push announced May 26.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Vaccine Company, Inc. (this deal) | 2026 | $1.6B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Neurology deals